Drug Trial Radar · NCT02648204
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
Last checked: Nov 20, 2026Latest source record: Oct 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,201
Actual
Start
Jan 6, 2016
Primary completion
Apr 10, 2017
Study completion May 19, 2017
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 6, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
semaglutideDrug
Administered subcutaneously (s.c., under the skin) once-weekly.
DulaglutideDrug
Administered subcutaneously (s.c., under the skin) once-weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: Week 0, week 40
Locations
209 sites in 17 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Tuscumbia, Alabama
Novo Nordisk Investigational Site
Chandler, Arizona
Novo Nordisk Investigational Site
Phoenix, Arizona
Novo Nordisk Investigational Site
Phoenix, Arizona
Novo Nordisk Investigational Site
Anaheim, California
Novo Nordisk Investigational Site
Buena Park, California
Novo Nordisk Investigational Site
Carlsbad, California
Novo Nordisk Investigational Site
Concord, California
Novo Nordisk Investigational Site
Huntington Park, California
Novo Nordisk Investigational Site
Lincoln, California
Novo Nordisk Investigational Site
Los Angeles, California
Novo Nordisk Investigational Site
Montclair, California
Novo Nordisk Investigational Site
Poway, California
Novo Nordisk Investigational Site
Riverside, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
Tustin, California
Novo Nordisk Investigational Site
Van Nuys, California
Novo Nordisk Investigational Site
Denver, Colorado
Novo Nordisk Investigational Site
Norwalk, Connecticut
Novo Nordisk Investigational Site
Clearwater, Florida
Novo Nordisk Investigational Site
Clearwater, Florida
Novo Nordisk Investigational Site
Coral Gables, Florida
Novo Nordisk Investigational Site
Edgewater, Florida
Novo Nordisk Investigational Site
Fort Lauderdale, Florida
Novo Nordisk Investigational Site
Kissimmee, Florida
Novo Nordisk Investigational Site
Miami, Florida
Novo Nordisk Investigational Site
Orlando, Florida
Novo Nordisk Investigational Site
Orlando, Florida
Novo Nordisk Investigational Site
Pembroke Pines, Florida
Novo Nordisk Investigational Site
Port Orange, Florida
Novo Nordisk Investigational Site
Tampa, Florida
Novo Nordisk Investigational Site
Tampa, Florida
Novo Nordisk Investigational Site
Adairsville, Georgia
Novo Nordisk Investigational Site
Atlanta, Georgia
Novo Nordisk Investigational Site
Bainbridge, Georgia
Novo Nordisk Investigational Site
Conyers, Georgia
Novo Nordisk Investigational Site
Marietta, Georgia
Novo Nordisk Investigational Site
Marietta, Georgia
Novo Nordisk Investigational Site
Suwanee, Georgia
Novo Nordisk Investigational Site
Meridian, Idaho
Showing 40 of 209 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.